{"name":"Eliem Therapeutics (UK) Ltd.","slug":"eliem-therapeutics-uk-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":46713000,"netIncome":-59851000,"cash":35685000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ETX-018810","genericName":"ETX-018810","slug":"etx-018810","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ETX-018810","genericName":"ETX-018810","slug":"etx-018810","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQSU1nZ0VqM3RfRGppZVpmaW9IaWEtSXFzMDVLc3QybFZPQnMyb2szcm0xeDB2UGNJeVQ1dUpEMlU4Sy0tamtsQ0lJV0Z4VGc4WFdkcjJTN0VJa1RhRXB6YWNNempmZURoRE95Y05ocktOeEFOeHdtcHkwT3d5NnYwTmNDNjNDVUFERkRNTk9BOVp6cU1SSmk0YUNKQQ?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key - openPR.com","headline":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxNelhGRWdNOUpyWkFNSHZzMml5MHFvYnpHMmVhN0RjRmZ6UW5WR0hMeTM2SG91enFaNUk0ODRmekxuQWxjMHo1eHRpRlR4ZXZLNFpIOEkzQTRMMnNDaWNiUXQtMFFON2VFSWRJUUp4MXUySklNUThyRXlVSlYyOEVyR1hENnBUT1gtQmtGTDE1clFDNmhYWWNGTG1VSVFWUXl1cnBSNW9Rdkdpa0FFU3RsWlZXVVVJc2VoOFZRZ1lPekVyTUtLZGNGM0cxMlZaQkstMFRzbkx5YVNHdzJmbm1qOEdKWFhQQ3dDNWFCZXJYS2JOUjhCM0Z2OVV0Z3NocUpVRTJSY3BKSzVoaVowOWpkZzROSXV3dkFVRm9EVVlxNmNPVmM?oc=5","date":"2025-04-08","type":"pipeline","source":"GlobeNewswire","summary":"Developmental and Epileptic Encephalopathies Market to - GlobeNewswire","headline":"Developmental and Epileptic Encephalopathies Market to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQdDR4RUhaMzdXWmc1VHN5QllhTW13ZU5kZUduc0otcmpoamJkYktUN015djVxUHRncnV6dGZrM1RvTGFDVlo4cWttVU1PUk40Y2liZWd5emZ6OUJBRUtsYVI1dTcydnBTZlF4dHgtQnQtbnRKSHIwZjNpRWhsSUZfMw?oc=5","date":"2025-02-20","type":"trial","source":"Market Data Forecast","summary":"Sciatica Treatment Market Size, Share & Growth Report, 2033 - Market Data Forecast","headline":"Sciatica Treatment Market Size, Share & Growth Report, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOWVVnTmlVT1NJN2hScnY4QzlVUW9GcDA4MUxfRl9RTWQ2RlVXZjhWYzMxTEI3V0JZbGF4RU5IYWlKbGdsVnBIOWdwdGRZcnJxN2s5RnVNMWVyU2h1QTdKaGV4VE5ZOEVOeDhBdDRmT3VvNm8xVEw5SDg5Nk4wazFKZkY3QUdYcGw2b3d0SEZB?oc=5","date":"2024-12-04","type":"pipeline","source":"Pharma Voice","summary":"The big rebrand: Why these 4 biopharmas changed their name this year - Pharma Voice","headline":"The big rebrand: Why these 4 biopharmas changed their name this year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNaGFRMHFFVlBvMWJDa2x0b1Fzb0FiVTBMVDFWem52YWRIS3V1a0RnUnQ4V0hpU2QtMTdMLTAyOC02LWV5dWd2NzZzNDlMTkhXRmxvazhVMUY4SERoV2E0YmxmNFBhR1J1N3BxNDN2anpSYXVfZlZXQXZYcW9OY2loMTVITDlZeW1GMEpibTg2TmNDaGVYX2ZLNjlqZk1leWR1ekE?oc=5","date":"2024-01-31","type":"deal","source":"Contract Pharma","summary":"Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma","headline":"Pharmaceutical Industry Mergers & Acquisitions Roundup","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":46713000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-59851000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":35685000,"cashHistory":[],"totalAssets":167744000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}